NOBIVAC® Lepto₄ Vaccine

Lepto₄ Vaccine

Proven effective against disease, mortality and urinary shedding. Featuring an even higher level of quality due to VacciPure^™ filtration.

Product Description

NOBIVAC^® LEPTO₄ WAS SHOWN TO BE EFFECTIVE AGAINST LEPTOSPIROSIS

The four-way leptospirosis vaccine is shown to be effective against disease, mortality and leptospiruria.

Proven effective against disease and mortality caused by 4 virulent Leptospira serovars²¹
Protects against liver dysfunction and thrombocytopenia¹
The only vaccine proven effective against mortality and leptospiruria
Prevents leptospiremia²²
Proven safe and well tolerated in multiple studies¹
Available in both a stand-alone and combination formulation (DAPPv)

product Label

Overview

Efficacy

Safety

Administration

Alternate

Disease Information

Indications:

Shown to be effective for vaccination of healthy dogs 8 weeks of age or older against Leptospira canicola, L. icterohaemorrhagiae, L. pomona and L. grippotyphosa.

Also shown to be effective against mortality and leptospiruria (shedding of Leptospira in the urine) caused by L. canicola, L. icterohaemorrhagiae, L. pomona and L. grippotyphosa.

NOBIVAC^® LEPTO₄ IS A SAFE CHOICE

Safety confirmed in a 749-dog field study¹
Well tolerated on subcutenous administration
Proven safe across a variety of breeds and ages
Now featuring an even higher level of quality due to the VacciPure^™ filtration

ADMINISTRATION AND DOSAGE

Proven to be uniformly safe in experimental tests, with no significant adverse reactions in extensive clinical trials.¹
Two 1 mL doses given 2-4 weeks apart
Contact your veterinarian or manufacturer for more information on revaccination frequency

ALSO AVAILABLE IN OTHER FORMULATIONS

DISEASE INFORMATION

Leptospirosis

Unmatched Protection of Nobivac^® Lepto₄:Two Critical Indications

1. SHEDDING: DEFENSE AGAINST URINARY SHEDDING CAUSED BY 4 KEY LEPTOSPIRA SEROVARS

PREVENT URINARY SHEDDING OF LEPTOSPIRES²²

A key objective of vaccination is to prevent urinary shedding of leptospires, which has potential zoonotic risk:^22,23

0% of dogs vaccinated with Nobivac^® Canine 1-DAPPv+L₄ developed leptospiruria
All of the control dogs challenged with L. canicola and L. grippotyphosa, 80% of control dogs challenged with L. icterohaemorrhagiae, and 50% of control dogs challenged with L. pomona developed leptospiruria

Nobivac^® Lepto₄ is shown to be effective against leptospiruria associated with

L. grippotyphosa
L. canicola
L. icterohaemorrhagiae
L. pomona

None of the dogs vaccinated with Nobivac ® Canine 1- DAPPv+L₄ developed leptospiremia
100% of the control dogs challenged with L. canicola, L. grippotyphosa, L. icterohaemorrhagiae and 75% of the control dogs challenged with L. pomona showed leptospiremia, indicating the severe challenge model

2. MORTALITY: THE ONLY LEPTOSPIROSIS VACCINE SHOWN TO BE EFFECTIVE AGAINST DISEASE AND MORTALITY

PROTECTION FOR DOGS FACING THE MOST SEVERE CHALLENGES²¹

No dogs vaccinated with Nobivac^® Canine 1-DAPPv+L₄ died or required euthanasia
54% mortality and euthanasia in control groups, reflecting the severity of challenge

Clinical efficacy results showed that Nobivac^® Canine 1-DAPPv+L₄ also prevented¹

Leptospiremia
- More than 85% of vaccinates had no leptospiremia; leptospires were cleared quickly from the blood in those that did
- By contrast, all control dogs had leptospiremia, and it lasted significantly longer, by days
Liver dysfunction
- Serum levels of bilirubin and AST* remained at normal levels in significantly more vaccinates
Thrombocytopenia
- Platelet counts remained in the normal range

* AST = aspartate aminotransferase

None of the dogs vaccinated with Nobivac ® Canine 1- DAPPv+L₄ developed leptospiremia
100% of the control dogs challenged with L. canicola, L. grippotyphosa, L. icterohaemorrhagiae and 75% of the control dogs challenged with L. pomona showed leptospiremia, indicating the severe challenge model

UNMATCHED PROTECTION

NOBIVAC^® LEPTO₄ IS THE CLEAR CHOICE WHEN COMPARED WITH OTHER

4-WAY LEPTOSPIROSIS VACCINES^24-27

VacciPure^™Filtration Technology

THE ADVANCED VACCIPURE™ FILTRATION TECHNOLOGY

FEWER TOTAL PROTEINS AND A MORE PURIFIED PRODUCT.

FILTRATION PROCESS LEADS TO IMPROVED VACCINES¹

To promote an even higher level of quality and allow for 0.5-mL vaccines, Merck Animal Health introduced the unique VacciPure filtration process for manufacturing Nobivac EDGE^® Lepto₄, Nobivac EDGE^® DAPPV+L₄, Nobivac^® Lepto₄, and Nobivac^® Canine 1-DAPPV+L₄.

A porous filtration membrane selectively removes extraneous proteins, salts, and solvents

The outcome –